Evelyn Shaw

Dr. Evelyn Shaw

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2017 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
ESEvelyn Shaw
Evelyn Shaw
ARAlexander Rombauts
Alexander Rombauts
FTFe Tubau
Fe Tubau
APARIADNA PADULLES-ZAMORA
ARIADNA PADULLES-ZAMORA
JCJordi Càmara
Jordi Càmara
JCJordi Carratala
Jordi Carratala

5 March 2003 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JCJordi Carratala
Jordi Carratala
BRB. Rosón
B. Rosón
NSNúria Sabé
Núria Sabé
ESEvelyn Shaw
Evelyn Shaw
ORO. del Rio
O. del Rio
FGF. Gudiol
F. Gudiol

1 October 2013 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
Juan P. HorcajadaJuan P. Horcajada
Juan P. Horcajada
ESEvelyn Shaw
Evelyn Shaw
BPB. Padilla
B. Padilla
VPV. Pintado
V. Pintado
ECE. Calbo
E. Calbo
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
The clinical and microbiological characteristics of community-onset healthcare-associated (HCA) bacteraemia of urinary source are not well defined. We conducted a prospective cohort study at eight tertiary-care hospitals in Spain, from October 2010 to June 2011. All consecutive adult patients hospitalized with bacteraemic urinary tract infection (BUTI) were included. HCA-BUTI episodes were compared with community-acquired (CA) and hospital-acquired (HA) BUTI. A logistic regression analysis was performed to identify 30-day mortality risk factors. We included 667 episodes of BUTI (246 HCA, 279 CA and 142 HA). Differences between HCA-BUTI and CA-BUTI were female gender (40% vs 69%, p <0.001), McCabe score II–III (48% vs 14%, p <0.001), Pitt score ≥2 (40% vs 31%, p 0.03), isolation of extended spectrum β-lactamase-producing Enterobacteriaciae (13% vs 5%, p <0.001), median hospital stay (9 vs 7 days, p 0.03), inappropriate empirical antimicrobial therapy (21% vs 13%, p 0.02) and mortality (11.4% vs 3.9%, p 0.001). Pseudomonas aeruginosa was more frequently isolated in HA-BUTI (16%) than in HCA-BUTI (4%, p <0.001). Independent factors for mortality were age (OR 1.04; 95% CI 1.01–1.07), McCabe score II–III (OR 3.2; 95% CI 1.8–5.5), Pitt score ≥ 2 (OR 3.2 (1.8–5.5) and HA-BUTI OR 3.4 (1.2–9.0)). Patients with HCA-BUTI are a specific group with significant clinical and microbiological differences from patients with CA-BUTI, and some similarities with patients with HA-BUTI. Mortality was associated with patient condition, the severity of infection and hospital acquisition.

11 June 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJoan-Pau Millet
Joan-Pau Millet
ESEvelyn Shaw
Evelyn Shaw
ÀOÀngels Orcau
Àngels Orcau
MCMartí Casals
Martí Casals
JMJose M. Miró
Jose M. Miró
TGThe Barcelona Tuberculosis Recurrence Working Group
The Barcelona Tuberculosis Recurrence Working Group
Tuberculosis (TB) recurrence can be due to reinfection or relapse. The contribution of each to TB incidence and the factors associated with recurrence are not well known. Effectiveness of TB control programs is assessed in part by recurrence rates. The aim of this study was to establish the recurrence rate of TB in Barcelona, the associated risk factors and the role of reinfection. A population-based retrospective longitudinal study was performed in Barcelona, Spain. TB patients with positive culture results who completed treatment between Jan 1st, 2003 and Dec 31st, 2006 were followed-up until December 31st, 2009 by the TB Control Program. The incidence rate of recurrence was calculated per person-year of follow-up (py). Kaplan-Meier and Cox regression methods were used for the survival analysis by calculating the hazard ratio (HR) with 95% confidence intervals (CI). Of the 1,823 TB cases identified, 971 fulfilled the inclusion criteria and 13 (1.3%) had recurrent TB. The recurrence rate was 341 cases per 100,000 py, 13 times higher than the TB incidence of the general population. Likelihood of TB recurrence at the 1st, 3rd and 5th year of follow-up was 0.1%, 1.4% and 1.6%, respectively. Factors associated with recurrence were HIV infection (HR: 4.7, CI: 1.4–15.7), living in the inner city district (HR: 3.9, CI: 1.3–11.8) and history of TB treatment (HR: 5.2, CI: 1.7–16.2). Genotyping results of recurrent cases were available for 6 patients (3 reinfections and 3 relapses). The rate of TB recurrence in Barcelona is low and most episodes occur within the first three years. Patients at higher risk of recurrence are co-infected with HIV, living in neighborhoods with high TB incidence or with a history of TB treatment. When available, genotyping results help determine whether the recurrence is due to reinfection or relapse.

17 May 2018 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
NENoa Eliakim-Raz
Noa Eliakim-Raz
TBTanya Babitch
Tanya Babitch
ESEvelyn Shaw
Evelyn Shaw
IAIbironke Addy
Ibironke Addy
IWIrith Wiegand
Irith Wiegand
NSNese Saltoglu
Nese Saltoglu
Background: Complicated urinary tract infections (cUTIs) are responsible for a major share of all antibiotic consumption in hospitals. We aim to describe risk factors for treatment failure and mortality among patients with cUTIs. Methods: A multinational, multicentre retrospective cohort study, conducted in 20 countries in Europe and the Middle East. Data were collected from patients’ files on hospitalised patients with a diagnosis of cUTI during 2013-2014. Primary outcome was treatment failure, secondary outcomes included 30 days all-cause mortality,among other outcomes. Multivariable analysis using a logistic model and the hospital as a random variable was performed to identify independent predictors for these outcomes. Results: A total of 981 patients with cUTI were included. Treatment failure was observed in 26.6% (261/981), all cause 30-day mortality rate was 8.7% (85/976), most of these in patients with catheter related UTI (CaUTI). Risk factors for treatment failure in multivariable analysis were ICU admission (OR 5.07, 95% CI 3.18-8.07), septic shock (OR 1.92, 95% CI 0.93-3.98), corticosteroid treatment (OR 1.92, 95% CI 1.12-3.54), bedridden (OR 2.11, 95%CI 1.4-3.18), older age (OR 1.02, 95% CI 1.0071.03-), metastatic cancer (OR 2.89, 95% CI 1.46-5.73) and CaUTI (OR 1.48, 95% CI 1.04-2.11). Management variables, such as inappropriate empirical antibiotic treatment or days to starting antibiotics were not associated with treatment failure or 30-day mortality. More patients with pyelonephritis were given appropriate empirical antibiotic therapy than other CaUTI [110/171; 64.3% vs. 116/270; 43%, p <0.005], nevertheless, this afforded no advantage in treatment failure rates nor mortality in these patients. Conclusions: In patients with cUTI we found no benefit of early appropriate empirical treatment on survival rates or other outcomes. Physicians might consider supportive treatment and watchful waiting in stable patients until the causative pathogen is defined.

1 March 2018 in Journal of Hospital Infection
Verified
Journal Article
Closed access
ESEvelyn Shaw
Evelyn Shaw
LGL. Gavaldà
L. Gavaldà
JCJordi Càmara
Jordi Càmara
RGR. Gasull
R. Gasull
SGS. Gallego
S. Gallego
MPMiquel Pujol
Miquel Pujol